Skip to main content
. 2016 Sep;108:292–304. doi: 10.1016/j.neuropharm.2016.04.016

Fig. 4.

Fig. 4

Effect of TCB-2, CP-809,101 and lorcaserin on interictal EEG. (A1) TCB-2 (3 mg/kg, n = 6) significantly reduced EEG power in the alpha (8–12 Hz) and gamma (30–80 Hz) bands compared to vehicle (n = 7). (A2) Mean normalized power change at 40 min compared to the relative time point in the vehicle injected animals (top) and raw EEG spectrum at 40 min compared to pre-drug (bottom). (B1) CP-809,101 (10 mg/kg, n = 6) significantly increased EEG power in the delta (1–4 Hz) and decreased power in the gamma band (30–80 Hz) compared to vehicle (n = 8). (B2) Mean normalized power change at 60 min compared to equivalent time point in the vehicle injected animals (top) and raw EEG spectrum at 60 min compared to pre-drug (bottom). (C1) In the lorcaserin treated animals (10 mg/kg) no individual point reached statistical significance after post-hoc testing, although a trend for an effect in the delta and gamma bands is visible at 40 min (C2). All values are normalized to the control period (−40 to 0 min), and are expressed as a percentage of their respective vehicle group. Values represent mean ± SEM. Asterisks indicate p < 0.05 for a given time bin in the treatment group vs the corresponding time bin in the vehicle group (two-way ANOVA, Sidak's multiple comparison test).